Apollo Hospitals Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

June 25, 2026
Posted by: Kunal Singla
Category: News

Apollo Hospitals Q1 Results FY27: Uniresearch projects Revenue Rs 6,870 Cr | PAT Rs 556 Cr (29-analyst consensus). Q4 FY26: Rev Rs 6,606 Cr | PAT Rs 551 Cr.

The Apollo Hospitals Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 29-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 6,870 Cr (+17.6% YoY) and PAT Rs 556 Cr (+26.0% YoY). Prepared by Ankit Jaiswal.

Click Here – Get Free Investment Predictions

Table of Contents

Apollo Hospitals Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 Results FY27 Uniresearch Prediction	YoY Change	Source
Apollo Hospitals Revenue (Rs Cr)	5,842	6,870	+17.6%	Uniresearch \| 29-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	441	556	+26.0%	Uniresearch \| 29-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 9,208	12-month view	–	Analyst consensus (29 analysts)

Predictions apply 29-analyst FY27 consensus (Rev +17.6%, PAT +26.0%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Apollo Hospitals Q4 FY26 Key Metrics – Baseline for Apollo Hospitals Q1 Results FY27

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	6,606	+18.1% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	551	+33.1% YoY	Consolidated quarterly financial data

What Analysts Are Saying About Apollo Hospitals Q1 Results FY27

Across 29 analysts covering Apollo Hospitals, the FY27 consensus projects revenue growth of +17.6% and profit growth of +26.0%, with an average 12-month price target of Rs 9,208. The Q1 Results FY27 prediction reflects this consensus applied to verified Q1 FY26 actuals.

Key Watchpoints for Apollo Hospitals

Revenue Delivery vs Consensus for Apollo Hospitals

The primary watchpoint is whether Revenue in Q1 Results FY27 delivers in line with the Uniresearch projection of Rs 6,870 Cr (+17.6% consensus growth). Q1 FY26 base was Rs 5,842 Cr.

PAT Performance in Q1 Results FY27

The PAT watchpoint is whether Apollo Hospitals achieves Rs 556 Cr (+26.0% growth from Q1 FY26 base of Rs 441 Cr). Q4 FY26 PAT was Rs 551 Cr.

Risks to the Apollo Hospitals Prediction

Below-Consensus Revenue Growth

If Revenue comes in below the +17.6% consensus, actual revenue would fall short of Rs 6,870 Cr.

PAT Pressure in Q1 Results FY27

The PAT prediction of Rs 556 Cr could be impacted by cost escalation not factored into the 29-analyst consensus of +26.0%.

Conclusion: Apollo Hospitals

The Apollo Hospitals Uniresearch prediction of Revenue Rs 6,870 Cr and PAT Rs 556 Cr is derived from the 29-analyst consensus FY27 growth rates applied to verified Q1 FY26 actuals. When Q1 Results FY27 are declared, investors can benchmark actual performance against this consensus prediction. Track live updates on Univest.

Track Apollo Hospitals Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live Q1 Results FY27 alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals – these are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on Apollo Hospitals

What is Uniresearch’s PAT prediction for Apollo Hospitals Q1 Results FY27?

Ans. Uniresearch projects Apollo Hospitals Q1 PAT at Rs 556 Cr, applying 29-analyst FY27 profit growth consensus of +26.0% to Q1 FY26 verified PAT of Rs 441 Cr.

What is the Revenue prediction for Apollo Hospitals Q1 Results FY27?

Ans. Apollo Hospitals Q1 Revenue is projected at Rs 6,870 Cr, applying +17.6% FY27 revenue consensus to verified Q1 FY26 base.

What were Apollo Hospitals Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 6,606 Cr (+18.1% YoY) and PAT was Rs 551 Cr (+33.1% YoY).

Does the Apollo Hospitals Q1 Results FY27?

Ans. No. All predictions in this article are derived from the 29-analyst consensus applied to verified Q1 FY26 actuals.

What is the analyst target price mentioned in the Apollo Hospitals Q1 Results FY27?

Ans. The 29-analyst consensus gives an average 12-month price target of Rs 9,208 for Apollo Hospitals.

What are the risks to the Apollo Hospitals Q1 Results FY27?

Ans. Risks include below-consensus revenue growth (target: +17.6%) and unexpected cost pressures impacting the +26.0% PAT consensus.

What is the Q1 FY26 base for the Apollo Hospitals Q1 Results FY27?

Ans. Q1 FY26 consolidated Revenue was Rs 5,842 Cr and PAT was Rs 441 Cr. These form the base for the Apollo Hospitals Q1 prediction.

News Q1 results

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.